Quick Answer
Lyell Immunopharma, Inc. reported R&D Expense of $182.94 million for fiscal year 2023.
Lyell Immunopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $182.94M | +14.9% |
| 2022 | $159.19M | +14.8% |
| 2021 | $138.69M | -23.9% |
| 2020 | $182.24M | +186.6% |
| 2019 | $63.59M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.17M | -28.7% | -19.2% |
| June 30, 2025 | $34.86M | -13.4% | -19.8% |
| March 31, 2025 | $43.45M | +0.6% | +10.0% |
| September 30, 2024 | $39.50M | -9.9% | -1.9% |
| June 30, 2024 | $40.26M | -15.2% | -6.7% |
| March 31, 2024 | $43.17M | -3.3% | -1.5% |
| September 30, 2023 | $43.85M | +5.4% | -7.6% |
| June 30, 2023 | $47.47M | +8.6% | +6.4% |
- Lyell Immunopharma, Inc. showed an increase of +14.9% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2023 period, Lyell Immunopharma, Inc.’s r&d expense has grown by 187.7% (from $63.59 million to $182.94 million).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 28, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: